11/11/20
Sanofi Pasteur announces another advancement in the fight to prevent meningococcal disease. MenQuadfi ™ (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine) has been approved by the FDA for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. This innovative new vaccine, MenQuadfi is approved for use in individuals 2 years of age and older and has impressive immunogenicity data. MenQuadfi does not prevent N meningitidis serogroup B disease. Visit MenQuadfi.com order from your Sanofi Pasteur Representative or call 1 800-VACCINE.